Chemicon International, a Serologicals subsidiary, has obtained exclusive rights to commercialise, market and distribute stem cell reagents developed at the ASCC to scientists all over the world
Chemicon International and the Australian Stem Cell Centre announce an exclusive agreement to commercialise stem cell products.
Initial products which will be available to researchers through Chemicon include a novel and proprietary stem cell isolation kit, various proteins, and antibodies.
The ASCC is assisting Chemicon in new product development in the research reagent area and expects that other life science tools will also become part of this exclusive research collaboration as they become ready to market.
Chemicon will have the first right of evaluation to commercialise these new research reagents developed by the ASCC.
In exchange, Chemicon will make an in-kind contribution of research tools for use by researchers in the ASCC laboratories as well as contribute funds, products and technical expertise to the new stem cell training programme recently launched by the ASCC.
"Chemicon is excited to partner with ASCC to bring a vast array of novel stem cell products and technologies to the market," said Jeffrey Linton, president of Chemicon and Upstate, which comprise Serologicals's research segment.
"This unique arrangement will benefit stem cell research worldwide by enabling access to the many innovative tools developed at the ASCC which will further accelerate research in this exciting area".
"The centre has and will continue to develop high-quality research tools through its research programs, which we believe should be available to all scientists to support the development of the entire stem cell industry.
"Chemicon is an ideal partner given its extensive stem cell product portfolio, expertise in international distribution and marketing, and dedication to the realization of the potential of stem cell research.
"In addition to distributing the ASCC's research reagents, Chemicon is committed to providing novel reagents to our scientists, supporting our training programs, and, most importantly, advancing world-class stem cell research, " said Hugh Niall, chief executive officer of the Australian Stem Cell Centre.
Chemicon International offers a broad range of research products, including specialty reagents, kits, antibodies, and custom products and services, to customers working in the areas of neuroscience, stem cell biology, cancer, and infectious disease research.
It is also a leading supplier of monoclonal antibodies, conjugates, antibody blends and molecular-based detection kits for use in diagnostic laboratories.
Chemicon focuses on basic and biomedical research, drug discovery, and diagnostics, allowing it to serve thousands of customers worldwide in the academic, clinical, biotechnology, and pharmaceutical sectors.
Acquired in 2003, Chemicon is a Serologicals company, based in Temecula, CA.
The Australian Stem Cell Centre is Australia's biotechnology centre of excellence.
The centre has partnered with nine leading Australian universities and research institutions and brings together a critical mass of outstanding Australian stem cell research that is internationally competitive and recognised.
The centre's principal objective is to integrate a national multi-institutional research and discovery programme to develop treatments for serious disease through the application of stem cells and related technologies.
The Australian Stem Cell Centre is funded by the Australian and Victorian governments.
